Heat shock transcription factor 1 protects against pressure overload-induced cardiac fibrosis via Smad3

Ning Zhou1, Yong Ye2, Xingxu Wang2

  • 1Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China.

Journal of Molecular Medicine (Berlin, Germany)
|January 17, 2017
PubMed

Insights

Heat shock transcription factor 1 (HSF1) protects against cardiac fibrosis by inhibiting Smad3 activation. HSF1 deficiency worsens fibrosis and heart dysfunction, highlighting its therapeutic potential in fibrotic heart disease.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Fibrosis Research

Background:

  • Cardiac fibrosis, characterized by stiffening and reduced compliance, is a major risk factor for heart failure.
  • Heat shock transcription factor 1 (HSF1) is an intrinsic cardioprotective factor, but its role in cardiac fibrosis is not fully understood.

Purpose of the Study:

  • To investigate the role of HSF1 in pressure overload-induced cardiac fibrosis.
  • To elucidate the underlying molecular mechanisms by which HSF1 regulates cardiac fibrosis.

Main Methods:

  • Utilized a mouse model of transverse aortic constriction (TAC) to induce pressure overload.
  • Employed HSF1 transgenic (TG) and knockout (KO) mice, alongside wild-type littermates.
  • Investigated HSF1 and Smad3 phosphorylation and nuclear distribution in cardiac tissue and fibroblasts.
  • Assessed cardiac fibrosis and dysfunction through histological and functional analyses.

Main Results:

  • HSF1 phosphorylation was downregulated in TAC-induced fibrotic hearts and mechanically stressed cardiac fibroblasts.
  • HSF1 overexpression attenuated TAC-induced cardiac fibrosis and dysfunction, while HSF1 deficiency exacerbated these conditions.
  • HSF1 inhibited the phosphorylation and nuclear translocation of Smad3, a key fibrotic mediator.
  • Direct binding between phosphorylated HSF1 and Smad3 was observed, which was disrupted by mechanical stress.

Conclusions:

  • HSF1 acts as a novel negative regulator of cardiac fibrosis.
  • HSF1 mitigates cardiac fibrosis by directly inhibiting Smad3 activation.
  • Modulating HSF1 activity may represent a therapeutic strategy for treating fibrotic heart disease.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
593
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.3K